TransMedics Group, Inc. (TMDX)
| Market Cap | 2.44B -42.3% |
| Revenue (ttm) | 635.89M +30.2% |
| Net Income | 171.92M +251.2% |
| EPS | 4.46 +216.8% |
| Shares Out | 34.56M |
| PE Ratio | 15.78 |
| Forward PE | 31.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,429 |
| Open | 71.99 |
| Previous Close | 71.37 |
| Day's Range | 70.56 - 73.50 |
| 52-Week Range | 60.11 - 156.00 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 116.78 (+65.65%) |
| Earnings Date | May 5, 2026 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $116.78, which is an increase of 65.65% from the latest price.
News
TransMedics Group Transcript: 46th Annual William Blair Growth Stock Conference
A transformative organ care system and vertically integrated logistics network have driven record organ utilization and double-digit growth, with ambitious targets to expand U.S. and global transplants through new technology and international partnerships. Focus remains on innovation, operational scale, and clinical excellence.
TransMedics price target lowered to $75 from $85 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on TransMedics (TMDX) to $75 from $85 and keeps a Hold rating on the shares. After having spoken with four U.S.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Group Proxy statement: Proxy filing
TransMedics Group filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
TransMedics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded TransMedics (TMDX) to Perform from Outperform without a price target post the Q1 report. The cites “pure exhaustion defending this name” for the downgrade. The clinical value pr...
TransMedics price target lowered to $140 from $157 at Baird
Baird analyst David Rescott lowered the firm’s price target on TransMedics (TMDX) to $140 from $157 and keeps an Outperform rating on the shares. The firm updated its model following…
TransMedics price target lowered to $85 from $130 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on TransMedics (TMDX) to $85 from $130 and keeps a Hold rating on the shares.
TransMedics price target lowered to $124 from $152 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on TransMedics (TMDX) to $124 from $152 and keeps a Buy rating on the shares. The firm said they released a…
TransMedics price target lowered to $120 from $190 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on TransMedics (TMDX) to $120 from $190 and keeps a Buy rating on the shares. The firm said its Q1…
TransMedics price target lowered to $142 from $174 at Needham
Needham lowered the firm’s price target on TransMedics (TMDX) to $142 from $174 and keeps a Buy rating on the shares. The company’s Q1 revenue and earnings missed consensus estimates,…
TransMedics falls -20.5%
TransMedics (TMDX) is down -20.5%, or -$19.43 to $75.50.
TransMedics Group Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and strong operational execution, despite regulatory headwinds and donor supply volatility. Major investments in technology, logistics, and international expansion support a reiterated 2026 revenue guidance of $727–$757 million.
TransMedics Group Earnings release: Q1 2026
TransMedics Group released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
TransMedics Group Quarterly report: Q1 2026
TransMedics Group has published its Q1 2026 quarterly earnings report on May 5, 2026.
TransMedics Group Slides: Q1 2026
TransMedics Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
TransMedics Reports First Quarter 2026 Financial Results
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics signs agreement to invest in PAD Aviation
TransMedics (TMDX) Group announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator. The proposed strategic investment is in...
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation...
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinic...
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics Group Proxy statement: Proxy filing
TransMedics Group filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
TransMedics Group Proxy statement: Proxy filing
TransMedics Group filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
TransMedics price target lowered to $118 from $170 at Evercore ISI
Evercore ISI lowered the firm’s price target on TransMedics (TMDX) to $118 from $170 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
TransMedics Group Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management outlined plans to deepen integration into the U.S. transplant ecosystem, highlighted robust clinical trial progress, and detailed ongoing European expansion and operational improvements. Regulatory decisions on further integration are expected by 2027, with significant growth anticipated in kidney and international markets.